Recreational Use, Analysis and Toxicity of Tryptamines

New psychoactive substances (NPS) comprise a broad and evolving set of compounds whose structures are similar to controlled drugs but differ enough to evade scheduling, and they are often marketed as "research chemicals", "incense" or other benign products. Tryptamines form one chemical class of NPS as well as a group of naturally occurring signalling molecules (notably serotonin and melatonin) and classical hallucinogens (for example psilocybin and DMT). Earlier research has established that small structural changes to the tryptamine core strongly influence receptor binding, pharmacology and subjective effects, and that many tryptamines are not detected by routine toxicology screens used in emergency settings. Tittarelli and colleagues set out to collate and organise available information on tryptamines and their derivatives, focusing on chemical classification, structure–activity relationships, routes of administration, pharmacology, reported effects (including user reports), toxicology, documented emergency-room and coronial case reports, fatalities, and analytical methods for detection. The study is presented as a comprehensive literature review that incorporates peer-reviewed publications together with non–peer-reviewed sources such as books, government reports and online drug-user fora, with the aim of producing a practical reference for clinicians, forensic scientists and public-health professionals.

The study is a comprehensive, narrative review of published literature and other information sources relating to tryptamines. The researchers searched scientific publications and supplemented these with non–peer-reviewed material including books, government documents, law-enforcement seizure reports and user reports from internet fora (for example Erowid). The extracted text does not provide a detailed, reproducible search strategy, dates searched, inclusion/exclusion criteria, or formal quality assessment of included sources. Content was organised around a chemical-structure classification (drawing on prior schemes such as those proposed by Nichols and by Fantegrossi), and the review considered: (1) chemical and structural variants of tryptamines (ring-unsubstituted, 4‑ and 5‑position modified, and ergolines); (2) structure–activity relationships and principal receptor affinities; (3) routes of administration, typical dosages, onset and duration of effects; (4) adverse effects, clinical intoxications and fatalities reported in emergency departments and at coronial investigations; and (5) analytical approaches for detection and confirmation (chromatography–mass spectrometry techniques and other laboratory methods). Case reports and toxicological analyses from the forensic literature were synthesised to illustrate clinical presentations and concentrations reported in fatal cases. Because the authors explicitly included internet user reports and law‑enforcement seizure data alongside peer‑reviewed studies, the review mixes data types and anecdotal evidence with formal toxicology and pharmacology findings; the extracted text does not state that any meta‑analytic statistical pooling was attempted.

The review summarises tryptamines by chemical subgroups and then presents pharmacology, typical use patterns, subjective effects, adverse events and forensic case examples for representative compounds. Classification and structure–activity relationships: The authors present two classification schemes (Nichols' distinction between simple tryptamines and ergolines, and Fantegrossi's division into unsubstituted, 4‑position and 5‑position modified tryptamines). They emphasise that substitutions on the indole ring and on the side chain alter receptor affinities and clinical effects: alpha‑methylation tends to confer stimulant properties (for example AMT, 5‑MeO‑AMT), while many simple and substituted tryptamines act as agonists at serotonin receptors, particularly 5‑HT2A and 5‑HT2C, with additional activity at other targets (5‑HT1A, adrenergic receptors, sigma‑1, and monoamine transporters in some cases). Ring‑unsubstituted compounds: AMT and AET are described as stimulant–psychedelic agents with monoamine‑releasing and reuptake‑inhibiting effects and oral activity; AMT doses reported by users range from about 15–30 mg orally (onset 3–4 hours, effects lasting up to 12–24 hours or longer), with common adverse effects including anxiety, nausea, dysphoria and sympathomimetic signs. AET has been linked to serotonin neurotoxicity in animal studies and to agranulocytosis when used previously as an antidepressant. DMT is a short‑acting potent agonist at 5‑HT2A/2C and other receptors; smoked or injected doses are typically 15–60 mg, onset is seconds to under a minute with effects lasting about 15 minutes, while oral DMT requires a monoamine oxidase inhibitor (MAOI) as in ayahuasca preparations. Other unsubstituted analogues (DET, DPT, DiPT) are orally active in many cases; DiPT is notable for producing auditory distortions rather than visual effects. 4‑position modified tryptamines: Psilocybin (a 4‑phosphoryloxy derivative converted to psilocin in vivo) is the prototypical 4‑position agent with oral doses commonly 6–20 mg of psilocybin, onset within 20–40 minutes and total duration of several hours. Synthetic 4‑OH analogues (for example 4‑HO‑DET, 4‑HO‑MiPT) are discussed largely through user reports and limited pharmacology. 5‑position modified tryptamines and methoxy derivatives: Bufotenine (5‑OH‑DMT) occurs naturally but may poorly cross the blood–brain barrier; route and dose substantially influence effects. Compounds such as 5‑MeO‑DMT, 5‑MeO‑AMT, 5‑MeO‑DiPT, 5‑MeO‑MiPT and 5‑MeO‑DALT have higher potency in many cases, interact with 5‑HT1A and 5‑HT2A receptors, and often inhibit serotonin reuptake. 5‑MeO‑DMT is rapidly acting and short lived but—when combined with MAOIs—can form active metabolites (notably bufotenine via CYP2D6 O‑demethylation) and produce prolonged exposure with risk of serotonin toxicity. Reported oral dosing ranges widely between substances (for example 5‑MeO‑AMT oral doses cited as 2.5–4.5 mg, with reported durations of 12–18 hours in some accounts). User reports and subjective effects: The review draws heavily on internet user accounts (for example Erowid) to summarise positive effects commonly described for many tryptamines: intense visual phenomena, altered perception of time, feelings of euphoria, increased sociability or libido and enhanced sensory experience. Adverse experiences frequently reported include anxiety, panic, frightening hallucinations, nausea, vomiting, palpitations, tremor, bruxism and impaired coordination. The authors note that user reports are inherently limited by uncertain product identity, dose and co‑ingestants. Clinical intoxications and non‑fatal emergency presentations: Case reports summarised include AMT overdoses producing marked sympathomimetic signs, agitation and visual hallucinations that typically responded to benzodiazepine sedation and supportive care. Examples include a 21‑year‑old ingesting 270 mg of AMT and a 17‑year‑old who ingested powder instead of insufflating it, both presenting with tachycardia, mydriasis and agitation. 5‑MeO‑DMT combined with harmaline (a natural MAOI) produced severe toxicity with hyperpyrexia (temperature 40.7 °C), tachycardia (heart rate 186 bpm) and agitation requiring restraint and benzodiazepines, illustrating dangerous MAOI–tryptamine interactions. 5‑MeO‑DiPT ("Foxy") exposures reported to poison‑control databases frequently involved agitation, hallucinations, tachycardia and confusion; in individual reports this compound has also been associated with rhabdomyolysis and acute renal impairment. Fatalities: The review documents multiple fatalities where tryptamines were implicated. A Miami case in 2003 is described in which AMT was detected post‑mortem and associated with a death after acute behavioural disturbance. Fatalities involving AET are reported with extensive post‑mortem tissue concentrations (for example heart blood 5.6 mg/L; urine 80.4 mg/L; liver, kidney and brain concentrations reported in mg/g). A 2005 case involving an ayahuasca‑like extract found 5‑MeO‑DMT at 1.88 mg/L in heart blood together with harmala alkaloids (tetrahydroharmine 0.38 mg/L, harmaline 0.07 mg/L, harmine 0.17 mg/L), and the death was attributed to hallucinogenic amine intoxication. A separate fatality after rectal administration of 5‑MeO‑DiPT reported blood levels of parent compound 0.412 µg/mL and metabolites 0.327 µg/mL (5‑OH‑DIPT) and 0.020 µg/mL (5‑MeO‑NIPT), with the medical cause recorded as acute cardiac failure due to neurotoxicity from overdose. The authors also note deaths associated with high doses and unsafe behaviours (for example fatal road incidents following intoxication) where quantification was incomplete. Analytical methods: Routine immunoassay screens often fail to detect tryptamines. Confirmatory and screening methods described include GC–MS and LC–MS techniques, UHPLC, various mass‑analyser types (single quadrupole, quadrupole ion trap, triple quadrupole with MRM/SRM, high‑resolution Orbitrap, TOF with MALDI), and sample preparation methods such as liquid–liquid extraction, solid‑phase extraction and protein precipitation. The review emphasises challenges: lack of reference spectra in libraries, uncommon fragmentation patterns, and the need for NMR or IR for structural elucidation when reference standards are unavailable.

Tittarelli and colleagues interpret their findings as evidence that tryptamines represent a chemically diverse group that spans naturally occurring signalling molecules, classic hallucinogens and an expanding set of novel psychoactive substances. They underline that small structural changes produce large differences in pharmacology and clinical effects, and that some modifications (for example alpha‑methylation) confer stimulant properties whereas others drive potent serotonergic agonism. The review highlights recurrent clinical themes: many tryptamines require only minute quantities to produce profound effects, several are short acting when inhaled or injected but long acting when taken orally, and co‑administration with monoamine oxidase inhibitors can dramatically increase toxicity and has been linked to severe illness and death. When positioning these results against earlier work, the authors stress that the literature is a patchwork of laboratory studies, case reports and user anecdotes. They argue that internet fora and law‑enforcement seizure reports, while imperfect, provide timely and practical intelligence about emerging compounds and usage patterns that may not yet appear in the peer‑reviewed literature. In terms of analytical practice, the discussion notes routine toxicology screens are often inadequate for tryptamines and recommends wider adoption of chromatographic‑mass spectrometric confirmatory methods and inclusion of new compounds in spectral libraries. The authors acknowledge important limitations of the evidence base they reviewed: many reports lack analytical confirmation, user accounts are subject to bias and uncertain dosing, epidemiological data are incomplete because surveillance systems do not systematically capture NPS exposures, and the review itself draws on non‑systematic searches of heterogeneous sources. These constraints limit the ability to estimate incidence or to make firm causal inferences from case reports. As implications, the paper calls for improved information‑sharing between forensic laboratories, poison centres, emergency departments and public‑health authorities; for enhanced laboratory capacity to detect and quantify tryptamines; and for policies that address the dynamic nature of internet‑based drug distribution. The authors propose that collated datasets combining analytical results, clinical case reports and monitored online reports would assist clinicians and forensic practitioners facing novel tryptamine exposures.

The review concludes that tryptamines encompass both well‑known natural hallucinogens and an expanding array of novel psychoactive analogues that pose emerging public‑health and forensic challenges. Because many tryptamines are potent at small doses, are variably active by different routes, and are frequently not detected by routine screens, they have been implicated in intoxications and fatalities. The authors recommend systematic sharing of analytical and clinical data, improved laboratory detection methods, and the use of internet‑sourced information alongside formal surveillance to better inform emergency clinicians, forensic scientists and policymakers facing this evolving threat.